Panitumumab

Vectibix 20 MG/ML Concentrado Para Solucion Para Perfusion

20 mg concentrado para solución para perfusiónSpainMarketedAuthorised 17 Dec 2007

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Panitumumab

Vectibix 20 MG/ML Concentrado Para Solucion Para Perfusion

20 mg concentrado para solución para perfusiónSpainMarketedAuthorised 17 Dec 2007

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

VectibixItaly · Concentrato per soluzione per infusione · Amgen Europe B.V.

Vectibix, concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Amgen Europe B.V.

VECTIBIX 20mg/mlRomania · 20mg/ml · conc. pt. sol. perf. · Amgen Europe B.V.

Vectibix®Serbia · 20mg/mL · koncentrat za rastvor za infuziju · Amicus SRB D.O.O.

Vectibix 20MG/ML Conc. Solution for InfusionSaudi Arabia · Amgen Manufacturing Limited

Vectibix Concentrate for Solution for Infusion 100 mg/vialSingapore · 100 mg/vial · infusion, solution concentrate · Amgen Biotechnology Singapore Pte LTD

VectibixUnited States · 10ML/200MG, 20ML/400MG, 5ML/100MG · injectable · Amgen

Packs

Pack	Code	Status
VECTIBIX 20 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial de 20 ml	660253

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Panitumumab
Strength: 20 mg
Dosage form: concentrado para solución para perfusión
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 17 Dec 2007
Registration: 07423003
Marketing authorisation holder: Amgen Europe B.V.
Procedure: EU centralised
Supply: Uso Hospitalario